HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.
June 12, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Innate Pharma and maintained a price target of $11.5, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100